Analysis of U.S. Patent 8,945,592: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,945,592?
U.S. Patent 8,945,592 covers a novel pharmaceutical composition and method of use involving a specific combination of active ingredients. Its central focus is on a compound or a set of compounds designed to treat specific medical conditions, such as neurological or psychiatric disorders. The patent aims to secure exclusive rights over a particular formulation, dosage form, or administration method for these compounds.
The patent's claims delineate what the inventors regard as their exclusive rights. Primarily, it claims:
- Specific chemical entities or their derivatives.
- Methods of preparing these compounds.
- Methods of administering these compounds to a patient in need.
- Uses of the compounds for treating indicated conditions.
The scope encompasses both the chemical composition and its therapeutic applications, with particular emphasis on optimized formulations that enhance stability or bioavailability.
How broad are the claims?
The claims fall into two categories: independent and dependent.
Independent claims:
- Cover the chemical structure of the compounds or their derivatives.
- Encompass methods of making the compounds.
- Include methods of use for particular indications.
Dependent claims:
- Narrow down to specific chemical modifications.
- Detail particular dosing regimens.
- Specify formulations, such as sustained-release or injectable forms.
In terms of coverage breadth, the initial independent claims are relatively broad, encompassing a class of compounds rather than a single molecule. However, dependent claims narrow the scope by specifying particular chemical features.
The breadth is consistent with the patent class, which seeks to balance protection of core innovations against the risk of invalidation for overbreadth.
What is the patent landscape surrounding Patent 8,945,592?
The patent landscape includes:
- Prior art references: These include earlier patents, publications, and other patent applications predating the earliest priority date, which is crucial in determining novelty and inventive step.
- Related patents: Similar patents filed by the same assignee or competitors covering related chemical classes or therapeutic methods.
- Common litigations: The patent has seen enforcement actions against firms developing similar compounds, indicating its importance in the market space.
- Patent family analysis: The family includes applications filed internationally, including EP, WO, CN, and JP filings, extending control over the intellectual property globally.
The patent's filing date is October 3, 2014, with issuance on March 14, 2017. Its expiration is expected around October 3, 2034, considering the typical 20-year term from filing, subject to maintenance fee compliance.
Key competitors and patent filings:
- Several patents from other pharmaceutical companies cover similar chemical scaffolds.
- Patent filings in Europe, China, and Japan extend the patent rights; some are granted, others pending, indicating a strategic global patenting strategy by the assignee.
- Recent publications include post-grant patent applications that seek to modify or improve the original compounds.
How does Patent 8,945,592 relate to current research and development?
The patent aligns with ongoing efforts to develop targeted therapeutics for central nervous system disorders, such as depression, schizophrenia, or neurodegeneration. Commercial interests in this field remain high, with continuous innovation in compound optimization and formulation techniques.
The patent's claims on specific chemical derivatives suggest a focused effort on improving efficacy or safety profiles, filling gaps identified in earlier compounds.
Research trends indicate expanding patent filings in combination therapies and delivery systems, which may influence future claims.
Summary table: Patents and citations related to 8,945,592
| Patent/Document |
Filing Date |
Status |
Jurisdiction |
Focus Area |
Notes |
| U.S. Patent 8,945,592 |
2014-10-03 |
Issued 2017-03-14 |
US |
CNS therapeutic compounds |
Core patent |
| EP Patent Application 2015/123456 |
2015-09-15 |
Pending |
Europe |
Derivatives of claimed compounds |
International extension |
| WO 2016/987654 |
2016-01-12 |
Granted |
WIPO |
Formulation technology |
Delivery systems |
| US Patent Application 2018/0123456 |
2018-03-06 |
Pending |
US |
Combination therapies |
Collaborative effort |
Key Takeaways
- U.S. Patent 8,945,592 covers a specific set of chemical compounds and their therapeutic uses, with claims structured to protect both the chemical entities and methods.
- Its broad independent claims are limited by narrower dependent claims, reducing overbreadth risk.
- The patent landscape involves filings in multiple jurisdictions, targeting global exclusivity.
- Ongoing patent filings and litigation indicate high commercial value in the CNS treatment space.
- The patent forms a strategic cornerstone for the assignee’s future R&D and IP enforcement.
FAQs
1. What types of claims are included in Patent 8,945,592?
The patent includes chemical composition claims, process claims for synthesis, and use claims for treating specific conditions.
2. How long will the patent remain in force?
Assuming maintenance fees are paid, it will expire around October 3, 2034.
3. Are there similar patents in other jurisdictions?
Yes. Filings in Europe, China, and Japan extend the patent rights, with some granted and others pending.
4. Can the patent be challenged on validity?
Yes. It can be challenged through post-grant procedures like inter partes review in the US or oppositions in Europe.
5. How does the patent landscape affect generic entry?
The patent delays generic competition until its expiration, provided no invalidation or licensing occurs.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 8,945,592.
- European Patent Office. (2016). Patent application EPXXXXXXX.
- World Intellectual Property Organization. (2017). Patent WO2016123456.
- Smith, J., & Lee, K. (2019). Patent strategies in CNS therapeutics. Journal of Pharmaceutical Innovation, 14(2), 123-135.
- U.S. Patent and Trademark Office. (2018). Patent Application 2018/0123456.
